HK Stock Market Move | EVEREST MED-B(01952) rises by over 3% with huge potential clinical demand. Nai Fukang is expected to usher in a period of outbreak in the domestic market.

, EVEREST MED-B (01952) rose by more than 3%, as of the press release, it rose by 3.31% to 37.4 Hong Kong dollars, with a turnover of 52.6304 million Hong Kong dollars. On the news front, recently, the innovative pharmaceutical company EVEREST MED-B's blockbuster product - the world's first IgA nephropathy targeted therapy drug Naifocan (Budenide enteric-coated capsules) NefIgArd III global open-label extension (OLE) study, announced positive data at the American Society of Nephrology Kidney Week 2024. The study analysis revealed that for IgA nephropathy patients who had completed the NefIgArd III trial, those who received a second course of treatment with Naifocan had estimated glomerular filtration rate (eGFR) and proteinuria benefits comparable to those of first-time treated patients, and good tolerability. This study result confirms that Naifocan can provide long-term targeted therapy for IgA nephropathy patients, bringing good news to many IgA nephropathy patients in China. It is worth noting that in this year's national medical insurance negotiation, Everest Med, representing emerging biopharmaceutical companies, Top New Glory, joined the negotiation as a designated company, and a series of clinical and commercial progress forecasts that the innovative product Naifocan is about to usher in an outbreak. It is understood that the prevalence of IgA nephropathy in Asia, including China, is much higher than in other parts of the world, with a 56% higher risk of progressing to end-stage kidney disease compared to other populations, and faster disease progression, there is a huge unmet clinical demand. As the first and only approved IgA nephropathy targeted therapy drug in the country, it is expected to reduce kidney function degradation by 50% and delay disease progression to dialysis or kidney transplant by 12.8 years, the market has a huge demand for Naifocan.